|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| Schizophrenia Pipeline Report | 1 | 1 |
| RECENT HIGHLIGHTS AND CHANGES | 3 | 1 |
| Recent Highlights and Changes Date Company Name | 3 | 1 |
| Trial Brief News Category | 3 | 1 |
| Date Company Name | 4 | 1 |
| UPCOMING PATENT EXPIRES BY THERAPY AREA | 5 | 1 |
| Patent Number Patent Expiry Date | 5 | 1 |
| SCHIZOPHRENIA PIPELINE OVERVIEW | 6 | 1 |
| Schizophrenia Projects by Phase of Development (% Share) | 6 | 1 |
| % of Projects (By Phase of Development) Phase | 6 | 1 |
| % of Projects | 6 | 1 |
| Schizophrenia Projects by Phase of Development | 7 | 1 |
| No. of Projects by Phase of Development Phase | 7 | 1 |
| No. of Projects | 7 | 1 |
| Marketed vs. Pipeline Products (I, II, III) | 8 | 1 |
| Marketed Vs. Pipeline Products Marketed Products | 9 | 1 |
| Pipeline | 9 | 1 |
| COMPANY OVERVIEW-PIPELINE PROJECTS | 10 | 1 |
| Company Overview-Pipeline Projects Company Name Inception Total Trials PC I II III A M | 10 | 1 |
| Company Name | 11 | 5 |
| Inception Total Trials PC I II III A M | 14 | 1 |
| Legend | 14 | 1 |
| Top 20 companies in late stage Schizophrenia Projects | 14 | 1 |
| Top 20 Companies in late stage (Phase II,III,Pending Approvals) | 14 | 1 |
| Top 20 companies in early stage Schizophrenia Projects | 15 | 1 |
| Top 20 Companies in Early stage (Preclinical,Phase I) Company Name Company Name | 15 | 1 |
| PIPELINE REVENUE | 16 | 1 |
| Sales Sales Value | 16 | 1 |
| FULL PIPELINE VIEW | 17 | 1 |
| Mechanism of Action Mode of Action Phase Description | 17 | 1 |
| Trial Details Presently it is in 2. Addex Pharmaceuticals SA (Private) | 17 | 1 |
| Prescription Trial Details Partnering Details | 17 | 1 |
| 3. Addex Pharmaceuticals SA (Private) | 17 | 1 |
| Phase Description | 17 | 1 |
| 4. Argolyn Bioscience Inc. (Private) | 18 | 1 |
| Drug Class Phase Description | 18 | 1 |
| Drug Class (EPHMRA) | 18 | 1 |
| Trial Details 5. Biocortech (Private) | 18 | 1 |
| Phase Description Drug Class (EPHMRA) | 18 | 1 |
| Trial Details 6. Clera Inc. (Private) | 18 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description Trial Details | 18 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 19 | 1 |
| Trial Details Partnering Details | 19 | 2 |
| 8. Marinus Pharmaceuticals, Inc. (Private) | 19 | 1 |
| Drug Class Mechanism of Action Phase Description | 19 | 1 |
| Chemical Name | 19 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Chemical/Biological Classification | 19 | 1 |
| Trial Details | 19 | 1 |
| Mechanism of Action | 20 | 1 |
| Mode of Action Phase Description | 20 | 4 |
| Drug Class (EPHMRA) | 20 | 2 |
| 10. Merck & Co Inc (MRK) | 20 | 1 |
| Phase Description | 20 | 1 |
| Route of Administration Trial Details | 21 | 1 |
| 12. Oakwood Laboratories, L.L.C. (Private) | 21 | 1 |
| Drug Class Mechanism of Action 5 | 21 | 1 |
| Chemical Name | 21 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 21 | 2 |
| Mechanism of Action 5 | 22 | 1 |
| Chemical Name Chemical Structure | 22 | 2 |
| Chemical/Biological Classification Trial Details | 22 | 1 |
| 15. Orexigen Therapeutics, Inc. (OREX) | 22 | 1 |
| Chemical/Biological Classification | 23 | 1 |
| 16. Ortho-McNeil, Inc. (Private) | 23 | 1 |
| Phase Description | 23 | 2 |
| Trial Details | 23 | 9 |
| Partnering Details | 23 | 2 |
| 17. Pfizer Inc (PFE) | 24 | 1 |
| 18. Pfizer Inc (PFE) | 24 | 1 |
| Mechanism of Action Mode of Action Phase Description | 24 | 1 |
| Drug Class Mechanism of Action 5 | 25 | 1 |
| Drug Class Mechanism of Action Phase Description | 25 | 1 |
| Chemical Name Chemical Structure | 25 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 25 | 2 |
| Chemical/Biological Classification Route of Administration Trial Details 22. QLT Inc (QLTI) | 25 | 1 |
| Mechanism of Action 5 | 26 | 1 |
| Chemical Structure | 26 | 1 |
| Chemical/Biological Classification Trial Details | 26 | 1 |
| Mechanism of Action Phase Description | 26 | 1 |
| Trial Details 24. Sanofi-Aventis (SNY) | 26 | 1 |
| 25. Sigma-Tau S.p.A. (Private) | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| Phase Description | 27 | 1 |
| Drug Class (EPHMRA) | 27 | 2 |
| 27. Taisho Pharmaceutical Co., Ltd. (Private) | 27 | 1 |
| 28. Targacept Inc (TRGT) | 28 | 1 |
| Drug Class Mechanism of Action Phase Description | 28 | 1 |
| Partnering Details | 29 | 4 |
| 29. Wyeth (WYE) | 29 | 1 |
| Phase I Pipeline View 1. Abbott Laboratories (ABT) | 29 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 29 | 1 |
| Route of Administration Trial Details | 29 | 1 |
| 2. Abbott Laboratories (ABT) | 30 | 1 |
| Mechanism of Action Mode of Action Phase Description | 30 | 2 |
| 3. ARYx Therapeutics, Inc. (ARYX) | 30 | 1 |
| Phase Description | 30 | 1 |
| 4. Astellas Pharma Inc (ALPMF) | 31 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 31 | 1 |
| Molecule Type Drug Class (EPHMRA) | 31 | 1 |
| 5. AstraZeneca Plc (AZN) | 31 | 1 |
| Chemical Name | 32 | 1 |
| Chemical Structure | 32 | 1 |
| Molecular Weight Molecule Type Pubchemid Trial Details | 32 | 1 |
| 7. EnVivo Pharmaceuticals (Private) | 32 | 1 |
| Drug Class Phase Description | 32 | 2 |
| Route of Administration Trial Details | 32 | 1 |
| 8. EUSA Pharma Inc. (Private) | 33 | 1 |
| Mechanism of Action Mode of Action Phase Description | 33 | 1 |
| Drug Class (EPHMRA) | 33 | 1 |
| Trial Details Presently it 10. GlaxoSmithKline plc (GSK) | 33 | 1 |
| Trial Details | 33 | 1 |
| 11. Grupo Ferrer (Private) | 33 | 1 |
| Drug Class Mechanism of Action 5 | 34 | 1 |
| Chemical Name | 34 | 1 |
| Chemical Structure | 34 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 34 | 1 |
| Chemical/Biological Classification | 34 | 1 |
| 12. Intra-Cellular Therapies, Inc. (ITI) (Private) | 34 | 1 |
| Mode of Action Phase Description | 35 | 1 |
| Drug Class (EPHMRA) | 35 | 1 |
| Trial Details | 35 | 4 |
| Partnering Details | 35 | 6 |
| 13. Janssen Pharmaceutica N V (Private) | 35 | 1 |
| Mechanism of Action Mode of Action Phase Description | 36 | 1 |
| 15. Neurogen Corporation (NRGN) | 36 | 1 |
| Phase Description | 37 | 2 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Chemical/Biological Classification Trial Details | 37 | 1 |
| 16. NeuroSearch A/S (Private) | 37 | 1 |
| Mechanism of Action Phase Description | 37 | 1 |
| Drug Class (EPHMRA) | 37 | 2 |
| Chemical/Biological Classification Trial Details | 38 | 1 |
| 18. NPS Pharmaceuticals Inc (NPSP) | 38 | 1 |
| Mechanism of Action Mode of Action Phase Description | 38 | 1 |
| 19. Pfizer Inc (PFE) | 39 | 1 |
| Phase Description Trial Details 20. Pfizer Inc (PFE) | 39 | 1 |
| PF3463275 Schizophrenia Mechanism of Action Unknown Mode of Action Antipsychotic Phase Phase I Description PF3463275 is Tria | 39 | 1 |
| Trial Details Presently 22. Rottapharm SpA (Private) | 39 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 39 | 1 |
| Chemical Name | 39 | 1 |
| Chemical Structure | 40 | 1 |
| Chemical/Biological Classification Trial Details | 40 | 1 |
| 23. Sanofi-Aventis (SNY) | 40 | 1 |
| Mechanism of Action Mode of Action Phase Description | 40 | 1 |
| Drug Class (EPHMRA) | 40 | 2 |
| Trial Details | 40 | 2 |
| Trial Details 25. Sanofi-Aventis (SNY) | 41 | 1 |
| Mechanism of Action Phase Description | 41 | 1 |
| Trial Details 26. Targacept Inc (TRGT) | 41 | 1 |
| Drug Class Mechanism of Action Phase Description | 41 | 1 |
| 27. Xytis, Inc. (Private) | 41 | 1 |
| Chemical Structure | 42 | 2 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 42 | 2 |
| Chemical/Biological Classification Trial Details | 42 | 3 |
| Partnering Details | 42 | 1 |
| Phase II Pipeline View 1. ACADIA Pharmaceuticals Inc (ACAD) | 42 | 1 |
| Mechanism of Action Mode of Action Phase Description | 42 | 1 |
| 2. ACADIA Pharmaceuticals Inc (ACAD) | 45 | 1 |
| Mechanism of Action 5 Mode of Action Phase Description | 45 | 1 |
| Chemical Name | 45 | 1 |
| Chemical Structure | 45 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 45 | 1 |
| Chemical/Biological Classification | 45 | 1 |
| Trial Details | 46 | 4 |
| Partnering Details | 48 | 1 |
| 3. Amarin Corporation plc (AMRN) | 48 | 1 |
| Phase Description | 48 | 1 |
| Chemical Name | 48 | 1 |
| Chemical Structure | 48 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Chemical/Biological Classification | 48 | 1 |
| Partnering Details | 50 | 1 |
| 4. BioLineRx, Ltd. (Private) | 50 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 50 | 1 |
| Molecule Type Drug Class (EPHMRA) | 50 | 1 |
| Route of Administration Trial Details | 51 | 1 |
| Partnering Details | 52 | 1 |
| 5. Chugai Pharmaceutical Co Ltd (CHGCF) | 52 | 1 |
| Mechanism of Action Mode of Action Phase Description | 52 | 1 |
| Trial Details | 52 | 2 |
| 6. CoMentis, Inc. (Private) | 52 | 1 |
| Drug Class Mechanism of Action Phase Description | 52 | 1 |
| Chemical Name | 52 | 2 |
| Chemical Structure | 53 | 3 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 53 | 3 |
| 7. Dainippon Sumitomo Pharma Co., Ltd. (Private) | 53 | 1 |
| Drug Class Mechanism of Action 5 | 53 | 1 |
| Phase Description | 53 | 1 |
| Prescription Trial Details | 54 | 1 |
| Partnering Details | 54 | 1 |
| 8. Eli Lilly & Co (LLY) | 54 | 1 |
| Drug Class Mechanism of Action | 54 | 1 |
| Mode of Action Phase Description | 54 | 1 |
| Trial Details | 55 | 5 |
| 9. Evotec AG (Private) | 55 | 1 |
| Drug Class Mechanism of Action 5 | 55 | 2 |
| Chemical Name | 55 | 1 |
| Chemical/Biological Classification | 55 | 1 |
| Partnering Details | 56 | 1 |
| 10. Fabre-Kramer Pharmaceuticals, Inc. (Private) | 56 | 1 |
| Phase Description | 56 | 1 |
| Drug Class (EPHMRA) | 56 | 2 |
| 11. Forest Laboratories Inc (FRX) | 57 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 57 | 1 |
| Partnering Details | 58 | 1 |
| 12. Gedeon Richter Ltd (GEDRF) | 58 | 1 |
| Drug Class Mechanism of Action Phase Description | 58 | 2 |
| 13. GlaxoSmithKline plc (GSK) | 59 | 1 |
| Drug Class Mechanism of Action 5 | 59 | 2 |
| Drug Class (EPHMRA) | 59 | 1 |
| 14. GlaxoSmithKline plc (GSK) | 59 | 1 |
| Chemical Name Chemical Structure | 59 | 1 |
| Chemical/Biological Classification Route of Administration Trial Details | 60 | 1 |
| 15. HoustonPharma, Inc. (Private) | 60 | 1 |
| Phase Description | 60 | 1 |
| 16. Laboratorios Almirall, S.A. (Private) | 60 | 1 |
| Chemical Name | 60 | 1 |
| Chemical Structure | 61 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 61 | 1 |
| Trial Details | 61 | 2 |
| Partnering Details | 61 | 1 |
| 17. Memory Pharmaceuticals Corp (MEMY) | 61 | 1 |
| Mechanism of Action Mode of Action Phase Description | 61 | 1 |
| Drug Class (EPHMRA) | 61 | 1 |
| Partnering Details | 63 | 1 |
| Mechanism of Action Phase Description | 64 | 2 |
| Drug Class (EPHMRA) | 64 | 1 |
| Trial Details | 64 | 3 |
| 19. Minster Pharmaceuticals plc (Private) | 64 | 1 |
| CASregistrynumber Drug Class (EPHMRA) | 64 | 1 |
| Chemical/Biological Classification | 64 | 1 |
| PF2545920 Schizophrenia Phase Phase II Description PF2545920 is being Trial Details Presently it is in 22. Pierre Fabre Medi | 65 | 1 |
| Drug Class Mechanism of Action Phase Description | 65 | 2 |
| Chemical Name Chemical Structure | 65 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Chemical/Biological Classification | 65 | 1 |
| 24. Roche Holdings Ltd (RHHBY) | 66 | 1 |
| Drug Class Phase Description | 66 | 1 |
| Molecule Type Drug Class (EPHMRA) | 66 | 1 |
| 25. Roche Holdings Ltd (RHHBY) | 66 | 1 |
| Partnering Details | 67 | 1 |
| Mechanism of Action Phase Description | 68 | 1 |
| Drug Class (EPHMRA) | 68 | 1 |
| Trial Details | 68 | 2 |
| 27. SK Bio-Pharmaceuticals (Private) | 68 | 1 |
| Mechanism of Action 5 | 68 | 1 |
| Mode of Action Phase Description | 68 | 1 |
| 28. Solvay S.A. (Private) | 69 | 1 |
| Drug Class Mechanism of Action 5 | 69 | 1 |
| Phase Description Drug Class (EPHMRA) | 69 | 1 |
| 29. Stem Cell Therapeutics Corp. (Private) | 69 | 1 |
| Phase Description Trial Details | 69 | 1 |
| Drug Class Mechanism of Action 5 Phase Description | 70 | 1 |
